Bristol Myers Squibb Company BMY

62.86 1.36 2.21% as of 25 Sep
Market cap
$125.9B
P/E
13.8×
Indexes indicate stock being part of an index,
Growth Flags show if company had growth for consecutive years

Bristol Myers Squibb Company (BMY) P/B ratio

As of 25 September 2026, Bristol Myers Squibb Company (BMY) trades at a P/B ratio of 5.8×. Over the past ten years it has ranged from 1.5× (March 2020) to 9.6× (February 2018); the current reading is higher than 55% of that period. That is above the Drug Manufacturers General industry median of 5.0× and above the Healthcare sector median of 2.5×.

P/B ratio, daily

Annual

Period P/B ratio Change
FY2025 5.9× (15.25%)
FY2024 7.0× 88.96%
FY2023 3.7× (25.15%)
FY2022 4.9× 28.60%
FY2021 3.8× 4.02%
FY2020 3.7× 74.65%
FY2019 2.1× (64.77%)
FY2018 6.0× (29.42%)
FY2017 8.5× 40.09%
FY2016 6.1× (23.56%)

Quarterly

Period P/B ratio Change
Jun 2026 5.3× (14.26%)
Mar 2026 6.1× 3.71%
Dec 2025 5.9× 20.09%
Sep 2025 4.9× (8.33%)
42 more quarters

Against its own ten years

Low 1.5× High 9.6×
Ten-year median 5.5×
Current reading's percentile 55

P/B ratio against peers

Company P/B ratio
SNY Sanofi compare 1.2×
PFE Pfizer Inc. compare 1.9×
GSK GSK PLC Sponsored ADR compare 4.3×
NVO Novo Nordisk A/S compare 5.0×
AZN AstraZeneca PLC compare 5.1×
BMY Bristol Myers Squibb Company 5.8×
NVS Novartis AG compare 6.6×
GILD Gilead Sciences, Inc. compare 16.0×
AMGN Amgen Inc. compare 19.2×
Drug Manufacturers General industry median 5.0×
Healthcare sector median 2.5×
Market median 1.8×

What P/B ratio is

Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.

Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))

The full definition of P/B ratio →

More on BMY